GLP-1 analogs could reduce the risks of microvascular complications of DM and are recommended for patients with cardiovascular disease or diabetic kidney disease in the American Diabetes Association (ADA) “Standards of Medical Care in Diabetes-2020” (American Diabetes Association, 2020a; American Diabetes Association, 2020b). This evidence concerns the gene GCG and diabetes mellitus.